<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of microbiology, epidemiology and immunobiology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of microbiology, epidemiology and immunobiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал микробиологии, эпидемиологии и иммунобиологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0372-9311</issn><issn publication-format="electronic">2686-7613</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">13249</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">RECOMBINANT HEAT-SHOCK PROTEIN (rHSP70) BOOSTS ACTIVATION OF INNATE AND ADAPTIVE IMMUNITY DURING SIMULTANEOUS ADMINISTRATION WITH BACTERIAL ANTIGENS IN EXPERIMENT</article-title><trans-title-group xml:lang="ru"><trans-title>РЕКОМБИНАНТНЫЙ БЕЛОК ТЕПЛОВОГО ШОКА (rHSP70) УСИЛИВАЕТ АКТИВАЦИЮ ВРОЖДЕННОГО И АДАПТИВНОГО ИММУНИТЕТА ПРИ СОВМЕСТНОМ ВВЕДЕНИИ С БАКТЕРИАЛЬНЫМИ АНТИГЕНАМИ В ЭКСПЕРИМЕНТЕ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shevchik</surname><given-names>Yu. S</given-names></name><name xml:lang="ru"><surname>Шевчик</surname><given-names>Ю. С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kurbatova</surname><given-names>E. A</given-names></name><name xml:lang="ru"><surname>Курбатова</surname><given-names>Е. А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sveshnikov</surname><given-names>P. G</given-names></name><name xml:lang="ru"><surname>Свешников</surname><given-names>П. Г</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Akhmatova</surname><given-names>N. K</given-names></name><name xml:lang="ru"><surname>Ахматова</surname><given-names>Н. К</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Egorova</surname><given-names>N. B</given-names></name><name xml:lang="ru"><surname>Егорова</surname><given-names>Н. Б</given-names></name></name-alternatives><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia</institution></aff><aff><institution xml:lang="ru">НИИ вакцин и сывороток им. И.И.Мечникова, Москва</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2009-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2009</year></pub-date><volume>86</volume><issue>1</issue><issue-title xml:lang="en">NO1 (2009)</issue-title><issue-title xml:lang="ru">№1 (2009)</issue-title><fpage>42</fpage><lpage>46</lpage><history><date date-type="received" iso-8601-date="2023-06-09"><day>09</day><month>06</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2009, Shevchik Y.S., Kurbatova E.A., Sveshnikov P.G., Akhmatova N.K., Egorova N.B.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2009, Шевчик Ю.С., Курбатова Е.А., Свешников П.Г., Ахматова Н.К., Егорова Н.Б.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder xml:lang="en">Shevchik Y.S., Kurbatova E.A., Sveshnikov P.G., Akhmatova N.K., Egorova N.B.</copyright-holder><copyright-holder xml:lang="ru">Шевчик Ю.С., Курбатова Е.А., Свешников П.Г., Ахматова Н.К., Егорова Н.Б.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://microbiol.crie.ru/jour/article/view/13249">https://microbiol.crie.ru/jour/article/view/13249</self-uri><abstract xml:lang="en"><p>Experimental study of adjuvant effect of recombinant mycobacterial heat-shock protein rHSP70 on immune response to antigens of opportunistic microorganisms was performed. Therapeutic polycomponent vaccine Immunovac-VP-4, containing ligands for binding with Toll-like receptors (TLRs) 2, 4 and 9, was used as a source of bacterial antigens. Obtained data showed that administration of rHSP70 mixed with bacterial antigens of opportunistic microorganisms leads to maturation of mice dendritic cells obtained from bone marrow precursors, increased expression of TLRs 2, 4, 9 on their surface and production of cytokines IL 1 β , IL-6, IL-10, TNF α , as well as to activation of innat e immunity in experiments in vivo resulting to increased resistance of mice to experimental Salmonella infection. Simultaneous administration of rHSP70 with bacterial antigens increased titers of antibodies to vaccine’s antigenic components in direct hemagglutination reaction. Thus, adjuvant effect of rHSP70 was confirmed on the used model as well as increase of stimulation of innate and adaptive immunity was shown.</p></abstract><trans-abstract xml:lang="ru"><p>Проведено экспериментальное изучение адъювантного действия рекомбинантного микобактериального белка теплового шока (rHSP70) на иммунный ответ к антигенам условно патогенных микроорганизмов. В качестве бактериальных антигенов использована терапевтическая поликомпонентная вакцина Иммуновак-ВП-4, содержащая лиганды для связывания с TLR 2,4,9. Полученные данные свидетельствуют о том, что rHSP70 в смеси с бактериальными антигенами условно патогенных микроорганизмов приводит к созреванию дендритных клеток, полученных из костномозговых предшественников мыши, повышению экспрессии на их мембране TLR2, 4, 9, выработке цитокинов IL-1β, IL-6, IL-10, TNFα, а также активирует врожденный иммунитет в опытах in vivo, повышая резистентность мышей при экспериментальной сальмонеллезной инфекции. Одновременное введение rHSP70 с бактериальными антигенами повышало титры антител к антигенным компонентам вакцины в РПГА. Таким образом, на данной модели подтверждено адъювантное действие rHSP70 и показано усиление стимуляции врожденного и адаптивного иммунитета.</p></trans-abstract><kwd-group xml:lang="en"><kwd>recombinant heat shock protein</kwd><kwd>bacterial antigens</kwd><kwd>adjuvant effect</kwd><kwd>experimental Salmonella infection</kwd><kwd>cytokines</kwd><kwd>dendritic cells</kwd><kwd>antibodies</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рекомбинантный белок теплового шока</kwd><kwd>бактериальные антигены</kwd><kwd>адъювантное действие</kwd><kwd>экспериментальная сальмонеллезная инфекция</kwd><kwd>цитокины</kwd><kwd>дендритные клетки</kwd><kwd>антитела</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Ахматова Н.К. Молекулярные и клеточные механизмы действия иммуномодуляторов микробного происхождения на функциональную активность эффекторов врожденного иммунитета. Автореф. дис. д-ра мед. наук, 2006.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Егорова Н.Б., Ефремова В.Н., Курбатова Е.А., Кузьмина Л.А. Итоги экспериментального и клинического изучения поликомпонентной вакцины из антигенов условно-патогенных микроорганизмов. Журн. микробиол. 1997, 6: 96—100.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Семенов Б.Ф., Егорова Н.Б., Семенова И.Б., Курбатова Е.А. Терапевтические вакцины. Рос. мед. вести. 2000, 3: 26—32.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Семенов Б.Ф., Зверев В.В. Концепция создания быстрой иммунологической защиты от патогенов. Журн. микробиол. 2007, 4: 93—100.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Agrawal S., Agrawal A., Doughty B. et al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signalregulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 2003, 171: 4984—4989.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Barrios C., Lussow A.R., Van Embden J. et al. Mycobacterial heat-shock protein as carrier molecules. II: The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and bacillus Calmette-Guerin priming. Eur. J. Immunol. 1992, 22 (6): 1365—1372.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ciupitu A., Peterson M.T., O’Donell C.L. et al. Immunization with a lymphatic choriomeningitis virus peptide mixed with heat shock protein 70 in protective antiviral immunity and specific cytotoxic T lymphocytes. J. Exp. Med. 1998, 187: 685—691.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Hong-Tao Li, Jia-Bin Yan, Jing Li et al. Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice. World J. Gastroenterol. 2005, 11 (9): 2858—2863.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Iwasaki A., Medzhitov R. Toll-like receptor of the adaptive immune responses. Nat. Immunol. 2004, 5: 987—995.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kawai T., Akira S. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 2005, 17: 338—344.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Napolitani G., Rinaldi A., Bertoni F. et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 2005, 6: 769—776.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Pulendran B. Variegation of the immune response with dendritic cells and pathogen recognition receptors. J. Immunol. 2005, 174: 2457—2465.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Querec T., Bennouna S., Alkan S. et al. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. JEM. 2006, 203: 413—424.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Roman E., Moreno C. Synthetic peptides noncovalently bound to bacterial hsp70 elicit peptide-specific T-cell response in vivo. Immunology. 1996,14: 487—492.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Wan T. Zhou X., Chen G. et al. Novel heat shock protein Hsp70L1 activates cells as Th1 polarizing adjuvant. Immunobiology. 2004,103: 1747—1754.</mixed-citation></ref></ref-list></back></article>
